Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib
Abstrakt
Chronic myeloid leukemia (CML) is a malignant hematopoietic disorder distinguished by the presence of a BCR-ABL1 fused oncogene with constitutive kinase activity. Targeted CML therapy by specific tyrosine kinase inhibitors (TKIs) leads to a marked improvement in the survival of the patients and their quality of life.
However, the development of resistance to TKIs remains a critical issue for a subset of patients. The most common cause of resistance are numerous point mutations in the BCR-ABL1 gene, followed by less common mutations and multiple mutation-independent mechanisms.
Recently, exosomes, which are extracellular vesicles excreted from normal and tumor cells, have been associated with drug resistance and cancer progression. The aim of the present study was to characterize the exosomes released by imatinib-resistant K562 (K562(IR)) cells.
The K562(IR)-derived exosomes were internalized by imatinib-sensitive K562 cells, which thereby increased their survival in the presence of 2 mu M imatinib. The exosomal cargo was subsequently analyzed to identify resistance-associated markers using a deep label-free quantification proteomic analysis.
There were >3,000 exosomal proteins identified of which, 35 were found to be differentially expressed. From this, a total of 3, namely the membrane proteins, interferon-induced transmembrane protein 3, CD146 and CD36, were markedly upregulated in the exosomes derived from the K562(IR) cells, and exhibited surface localization.
The upregulation of these proteins was verified in the K562(IR) exosomes, and also in the K562(IR) cells. Using flow cytometric analysis, it was possible to further demonstrate the potential of CD146 as a cell surface marker associated with imatinib resistance in K562 cells.
Taken together, these results suggested that exosomes and their respective candidate surface proteins could be potential diagnostic markers of TKI drug resistance in CML therapy.